Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Instagram Outage Disrupts Thousands of U.S. Users 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Dublin, Nov. 27, 2017 -- The "Blood Disorders Pipeline Database - 2017 Update" report has been added to Research and Markets' offering.
Blood Disorders Pipeline Highlights Database - 2017 Update, provides most up-to-date information on key pipeline products in the global Blood Disorders Drug market. It covers emerging therapies for Blood Disorders in active clinical development stages including early and late stage clinical trials. Key indications covered in this database include Neutropenia, Sickle-cell Disorders, Thalassemia, Iron deficiency anemia, Haemophilia A, and Haemophilia B. The pipeline data is presented in an excel dashboard with filtering options.
The pipeline data presented in this database helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.
By Indication:
The database presents pipeline by Blood Disorders indications. Key indications covered in this database include Neutropenia, Sickle-cell Disorders, Thalassemia, Iron deficiency anemia, Haemophilia A, and Haemophilia B.
By Clinical Trial Stages:
The database provides Blood Disorders pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.
By Drug Mechanism Classes:
The database provides Blood Disorders pipeline products by their dominant drug mechanism class. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.
By Company:
The database provides Blood Disorders pipeline products by the company.
For more information about this report visit https://www.researchandmarkets.com/research/z22xpl/blood_disorders
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Hematological Drugs
